A Phase 3 interventional study of Metformin 850 mg oral tablet bid and Supplemental fiber mixture (35 g total) composed of 6g of Oligofructose + 12g of resistant maltodextrin + 12g of acacia gum + 5g of PGX. in Obesity, Childhood and Insulin Resistance, sponsored by University of Alberta. Recruiting at 1 site in Canada. Open to participants aged 12 Years to 18 Years. Per ClinicalTrials.gov, last updated 2026-10-23.
Sponsored by University of Alberta · Phase 3, Interventional, and Treatment
How we know · 3 judgments
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 51 studies in Pediatric Obesity with a site in Canada — 7 open to participants now, 9 under way, 1 of them phase 3. Pediatric Obesity · Canada.
Among the 51 studies in Pediatric Obesity with a site in Canada, this one is the 19th largest by planned enrollment of the 40 interventional ones that give a count, is one of 6 that started in 2021, is the only one in phase 3, and was the 38th registered.
1,132 studies on the registry are indexed under Pediatric Obesity; 183 are open to participants now.
Browse Pediatric Obesity studies →7 of the 51 studies in Pediatric Obesity with a site in Canada are open now. Recruiting first, the newest first:
Hamilton Health Sciences Corporation · Sites in Canada
Ages 5–11 · Healthy volunteers
University of Victoria · Sites in Canada
Ages 6–12 · Healthy volunteers
St. Justine's Hospital · Sites in Canada
Ages 12–18
The Hospital for Sick Children · Sites in Canada
Ages 18 mo–60 mo · Healthy volunteers
University of Alberta · Sites in Canada
Ages 6–17
A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →
Of the 119 Pediatric Obesity studies recruiting now, 16 (13%) set no upper age limit and 101 (85%) stop at 75 or younger; 110 take children under 18; 67 take healthy volunteers.
This study: 12 Years to 18 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
51 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 6 started in 2021.
This study's planned enrollment of 90 is close to the median of 100 across 872 interventional studies indexed under Pediatric Obesity.
Median enrollment 73 across the 40 interventional studies, 54 across the 11 observational. Of the 36 that completed or were terminated, 2 (6%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 51 has an industry lead sponsor. The 10 most frequent:
University of Alberta is the lead sponsor of 825 studies on the registry; 172 are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 3 (60%) have results posted.
University of Alberta has 9 studies filed under Pediatric Obesity — fewer than ten, so there is no comparison to draw.
3 of the studies in Pediatric Obesity with a site in Canada that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04578652Phase 3University of AlbertaFiber and Metformin Combination Therapy in Adolescents With Severe Obesity and Insulin Resistance | 2027-02 |
| NCT05534711University of GuelphThe Family Stress Study - Chronic Stress and Child Adiposity: Testing a Bio-behavioural Model | 2027-05-30 |
| NCT06844786Hamilton Health Sciences CorporationSCORE! ACTIVE Trial | 2027-08-15 |
Add all 3 to your calendar (.ics) → With an account.
Among the 51 studies in Pediatric Obesity with a site in Canada, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a 12-month, single center, three-arm parallel design, double-blind, randomized clinical trial, to compare the effects of supplemental dietary fiber and metformin (MET) alone and in combination over 12 months on glucose metabolism (insulin resistance [IR]), inflammation and BMI in adolescents with obesity and IR, and to assess the relationship between therapeutic intervention(s) and changes in gut microbiome composition and function.
Since MET and FIBER have been shown to reduce weight and increase insulin sensitivity through distinct but overlapping mechanisms of action, our central hypothesis is that the combination of FIBER + MET will have a synergistic effect and be more effective than FIBER or MET alone in improving metabolic function (IR) and reducing BMI and inflammation in adolescents with obesity, IR and family history (FM) of T2DM.
.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
MET (850 mg po bid - standard of care) + Fiber placebo daily
Drug: Metformin 850 mg oral tablet bid
Fiber supplementation \[35g fiber daily\] + MET placebo po bid
Dietary Supplement: Supplemental fiber mixture (35 g total) composed of 6g of Oligofructose + 12g of resistant maltodextrin + 12g of acacia gum + 5g of PGX.
Fiber supplementation \[35g fiber daily\] + MET 850 mg po bid
Drug: Metformin 850 mg oral tablet bid · Dietary Supplement: Supplemental fiber mixture (35 g total) composed of 6g of Oligofructose + 12g of resistant maltodextrin + 12g of acacia gum + 5g of PGX.
MET dose: 500 mg daily, increasing to 500 bid if tolerated after 2 weeks, then increasing again 2 weeks later to 850 mg bid (1700 mg daily).
The first week of treatment will use 1/3 the daily treatment dose; then 2/3 dose for the second and third weeks; then the full dose thereafter, to allow time for adaptation.
Changes in HOMA-IR
Change in HOMA-IR value
Time frame: Baseline, 6, and 12 months
Changes in body weight
Body weight measured in kg
Time frame: Baseline, 6, and 12 months
Changes in body mass index (BMI)
BMI percentile and z-score according to age and sex will be estimated
Time frame: Baseline, 6, and 12 months
Changes in body composition
Body density using air-displacement plethysmography will be assessed to estimate fat mass and fat-free mass.
Time frame: Baseline, 6, and 12 months
Changes in inflammation
Markers of inflammation that will be measured are: high-sensitivity C-reactive protein, interleukin, tumor necrosis factor-alpha)
Time frame: Baseline, 6, and 12 months
Changes in metabolic function
The markers of metabolic function that will be measured are: fasting glucose, lipids (total, high and low density lipoprotein cholesterol; triglycerides), and oral glucose tolerance test.
Time frame: Baseline, 6, and 12 months
Changes in satiety hormones
Markers of satiety that will be measured are: acylated ghrelin, peptide tyrosine tyrosine, GLP-1, leptin, and adiponectin.
Time frame: Baseline, 6, and 12 months
Changes in quality of life
Quality of life will be measured by the a questionnaire
Time frame: Baseline, 6, and 12 months
Changes in perceived hunger and satiety
Perceived hunger and satiety will be assessed by a questionnaire
Time frame: Baseline, 6, and 12 months
Changes in gut microbiota composition
Fecal microbiota composition will be characterized by 16S rRNA gene amplicons sequencing using taxonomic and non-taxonomic based approaches.
Time frame: Baseline, 6, and 12 months
Changes in gut microbiome functions
Fecal microbiome functions will be assessed through whole metagenomic sequencing, stool SCFAs and bile acids, and plasma metabolomics.
Time frame: Baseline, 6, and 12 months
Changes in intestinal barrier integrity
Plasma lipopolysaccharide-binding protein and fecal calprotectin will be determined as measures of gut barrier integrity
Time frame: Baseline, 6, and 12 months
Plan to share: No
Started Oct 2021 (actual). Primary completion is estimated for Feb 2027, 64 months after the start.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 23, 2026: primary completion Sep 2026 → Feb 2027 and completion Sep 2026 → Feb 2027.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.